Companies: 10,795·Total market cap: $144.5T
Heron Therapeutics, Inc.

Heron Therapeutics, Inc.

HRTXNASDAQHealthcare● Active
$0.45
+$0.03(+6.13%)
Market Cap$71641543
P/E Ratio—
52W High$2.3
52W Low$0.42
ForecastMarket CapPE Ratio

Heron Therapeutics, Inc.（HRTX）股价预测与分析师目标价

华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。

hrtx · 股价预测 · 19 位分析师（近3月）· FMP · 更新于 2026年6月9日

分析师评级与共识

基于过去 3 个月内 19 位华尔街分析师

SellBuy

Buy

19 位分析师

共识

评级分布

Strong Buy
0
Buy
18
Hold
1
Sell
0
Strong Sell
0
合计: 19 · 买入占比: 94.7%

12 个月目标价

High

$9.00

Consensus

$6.67

+1370.5% upside

Low

$5.00

Median: $6 · Last Close: $0.45

Heron Therapeutics, Inc.（HRTX）的分析师共识为 Buy，基于过去 3 个月内 19 位华尔街分析师的评级。HRTX 的 12 个月平均目标价为 $6.67，相对当前价 $0.45 代表 +1370.5% 的潜在上行空间。

12 个月目标价预测

历史收盘价 + 分析师 12 个月目标价预测区间

分析师目标价覆盖不足，无法为该股票生成预测图表。

短期股价预测

Low Activity

算法生成 · 每日更新

DatePredicted PriceChange
2026-06-10$0.45↑ 0.00%

1-day model range: $0.44–$0.47. Peak: $0.47 (+0.00%).

长期股价预测

⚠️ 在满 252 个交易日历史（IPO/上市时间较短）前不展示长期预测；短期标签页仍可能显示模型输出。

基于技术分析的股价预测

14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明

🚫

Insufficient Trading Activity — Sentiment Signals Disabled

This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.

RSI (14)50.0
MACDNEUTRAL

Moving Averages · HRTX · Jun 9, 2026

Simple Moving Average (SMA)
MA 5$0.45BUY
MA 10$0.00NEUTRAL
MA 20$0.00NEUTRAL
MA 50$0.00NEUTRAL
MA 100$0.00NEUTRAL
MA 200$0.00NEUTRAL
Current $HRTX · Price above MA = BUY signal
Exponential Moving Average (EMA)
EMA 5$0.45BUY
EMA 10$0.00NEUTRAL
EMA 20$0.00NEUTRAL
EMA 50$0.00NEUTRAL
EMA 100$0.00NEUTRAL
EMA 200$0.00NEUTRAL
Current $HRTX · Price above MA = BUY signal
How we calculate: Technical sentiment is derived from 14 indicators — SMA(5,10,20,50,100,200), EMA(5,10,20,50,100,200), RSI(14), and MACD(12,26,9) — calculated from historical EOD price data. BUY = current price above MA; SELL = below. 14 TA signals + historical EOD price data · Updated daily. Independent of analyst consensus data. Not investment advice.

最新分析师评级与调整

Filter:
HC Wainwright & Co.2026-06-03
Maintains
Buy→Buy
Needham2026-06-03
Downgrade ↓
Buy→Hold
HC Wainwright & Co.2026-01-09
Maintains
Buy→Buy
Needham2025-08-08
Maintains
Buy→Buy
Needham2025-04-11
Maintains
Buy→Buy
Needham2025-02-28
Maintains
Buy→Buy
Needham2024-12-04
Maintains
Buy→Buy
Needham2024-11-13
Maintains
Buy→Buy
Needham2024-09-25
Maintains
Buy→Buy
Needham2024-08-07
Maintains
Buy→Buy

Wall Street analysts have recently issued updated ratings on Heron Therapeutics, Inc. (HRTX) stock. Of the recent 55 rating actions, 0 were upgrades and 2 were downgrades. 19 analysts currently cover HRTX.

分析师推荐趋势

Buy ratings1 → 1
Hold ratings0 → 1↑ +1
Sell ratings0 → 0

HRTX analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.

财务预测：EPS 与营收一致预期

Revenue This Year

$168M

↓ 16.9% YoY

Revenue Next Year

$176M

↑ 4.6% YoY

EPS This Year

$-0.05

EPS Next Year

$-0.01

↓ 81.2% YoY

EPS ForecastReported vs Estimated

Reported EPSHistorical estimateAnalyst forecast (future)

Analysts forecast HRTX EPS of $-0.05 for the current fiscal year, based on estimates from 1 analysts. The HRTX revenue forecast is $168M for the current year. These are analyst consensus estimates via FMP / S&P Global.

关于预测与目标价

HRTX 股价预测由两类独立数据源支撑：来自 19 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。HRTX 的共识目标价为 $6.67（+1370.5% 上行空间），分析师共识为 Buy。

HRTX 的短期预测（明日）为 $0.45（+0.00%）。

Heron Therapeutics, Inc. 在 NASDAQ 上市，代码 HRTX。HRTX 在 2027 年的整体展望偏积极，在覆盖分析师中约 95% 对应 Buy 共识。

常见问题答案综合分析师目标价、一致预期及页面展示的模型结果。

相关页面

盈利营收市盈率财务报表市值内幕交易股息价格历史

常见问题

HRTX 预测 · 8 个问题

根据 19 位华尔街分析师，HRTX 的 12 个月平均目标价为 $6.67，最高 $9.00、最低 $5.00。若有图表，中位目标价可在上方查看。相对当前价 $0.45，隐含约 +1370.5% 的上行空间。

HRTX 目标价HRTX 分析师目标价HRTX 12个月目标价目标价 HRTX

· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)

⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.